A major turning point has been reached in the fight against the resurgent viral disease Mpox with the announcement by the World Health Organization (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC) of Mpox as a worldwide public health emergency. The declaration highlights the urgent need for coordinated global action, especially in areas like Africa where access to life-saving treatments like vaccines remains limited and the health infrastructure is frequently strained.
Mpox: An Emerging Worldwide Threat
Long endemic in some regions of Central and West Africa, mpox was formerly known as monkeypox. But subsequent outbreaks in non-endemic areas have sparked concerns, prompting the designation of a worldwide public health emergency. Fever, rash, and enlarged lymph nodes are the disease's hallmarks. It can cause serious consequences and even death, especially in susceptible groups such as young children, pregnant mothers, and people with weakened immune systems.
Long endemic in some regions of Central and West Africa, mpox was formerly known as monkeypox. But subsequent outbreaks in non-endemic areas have sparked concerns, prompting the designation of a worldwide public health emergency. Fever, rash, and enlarged lymph nodes are the disease's hallmarks. It can cause serious consequences and even death, especially in susceptible groups such as young children, pregnant mothers, and people with weakened immune systems.
There have been reports of Mpox outbreaks in at least 12 African countries, including previously unaffected countries like Burundi, Kenya, Rwanda, and Uganda. 517 deaths and 2,863 cases have been confirmed so far in 2024 in these countries, mostly in the Democratic Republic of the Congo (DRC). Over 17,000 suspected cases have been reported on the continent thus far, an increase from 7,146 instances in 2022 and 14,957 cases in 2023. When we take into account the numerous flaws in contact tracking, laboratory testing, and monitoring, this is simply the tip of the iceberg.
Vaccine Distribution and Availability: A Serious Deficit
One of the best ways to prevent the spread of mumps is through vaccination. There are currently a number of vaccinations available for the mumps. Three of these (MVA-BN, LC16, and OrthopoxVac) have also been permitted for use for the prevention of the mpox. As vaccination has been shown to be effective in preventing the disease, only those who are at risk (such as those who have been in close contact with a person who has the mpox or those who belong to a group at high risk for exposure to the disease) should be considered for the vaccine. Nonetheless, there are still large differences in the global distribution of these vaccines between high- and low-income nations.
One of the best ways to prevent the spread of mumps is through vaccination. There are currently a number of vaccinations available for the mumps. Three of these (MVA-BN, LC16, and OrthopoxVac) have also been permitted for use for the prevention of the mpox. As vaccination has been shown to be effective in preventing the disease, only those who are at risk (such as those who have been in close contact with a person who has the mpox or those who belong to a group at high risk for exposure to the disease) should be considered for the vaccine. Nonetheless, there are still large differences in the global distribution of these vaccines between high- and low-income nations.
There are sadly insufficient vaccinations available in Africa, where mumps have historically been endemic. The necessary dosages considerably outweigh the supply, leaving a crucial gap that might jeopardize attempts to contain the outbreak. This gap affects global health equity in addition to being a logistical problem.
Comments
Post a Comment